Using a biosensor platform for the detection and characterization of autoantibodies in myasthenia gravis patients
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction, characterized by skeletal muscle weakness and fatiguability. 85-90% of MG patients have antibodies targeting the nicotinic acetylcholine receptor (AChR), an ion channel on the postsynaptic muscle membran...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2014
|
| Online Access: | http://hdl.handle.net/2429/46544 |